Sarepta Therapeutics Inc
NASDAQ:SRPT
Products, Regulatory, Earnings Announcements
Sarepta Announces Results From Ongoing Momentum Study, Phase 2 Clinical Trial Of SRP-5051
Published: 12/07/2020 14:01 GMT
Sarepta Therapeutics Inc (SRPT) - Sarepta Therapeutics Inc - Announced Results From Ongoing Momentum Study, a Phase 2 Clinical Trial of Srp-5051.
Sarepta Therapeutics Inc - Srp-5051 Was Generally Well-tolerated Across All Doses Studied, With No Clinical Or Laboratory Findings Reported.
Sarepta Therapeutics Inc - Results Support Continued Dose Escalation of Srp-5051 and Further Clinical Development.
Sarepta Therapeutics Inc - Srp-5051 Was Generally Well-tolerated Across All Doses Studied, With No Clinical Or Laboratory Findings Reported.
Sarepta Therapeutics Inc - Results Support Continued Dose Escalation of Srp-5051 and Further Clinical Development.
Revenue is expected to be $242.4 Million
Adjusted EPS is expected to be -$1.33
Next Quarter Revenue Guidance is expected to be $258.46 Million
Next Quarter EPS Guidance is expected to be -$1.56
More details on our Analysts Page.
Adjusted EPS is expected to be -$1.33
Next Quarter Revenue Guidance is expected to be $258.46 Million
Next Quarter EPS Guidance is expected to be -$1.56
More details on our Analysts Page.